• PlantX recently announced that its wholly owned UK-based subsidiary, Bloombox, has partnered with Disney in a co-branded campaign
• The campaign, aimed at promoting Bloombox products and celebrating the release of Disney’s new adventure-filled film, Jungle Cruise, will feature the launch of exotic plants, a treasure hunt, and a social media campaign
• According to PlantX CEO Lorne Rapkin, the collaboration legitimizes the company’s presence in the plant-based space, supporting the fact that it is indeed a true player in the space
• The company considers the partnership an opportunity to celebrate plants and their integral role and impact across the film industry

In a recent interview with Steve Darling from Proactive, newly appointed PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) CEO Lorne Rapkin noted that the company has accelerated its position thus far in part through exciting, accretive acquisitions. These acquisitions have provided “a really nice covering of all different verticals currently, and now we are just looking to enhance that” (https://ibn.fm/peOcp). In what appears to be a fulfillment of the commitment to enhance coverage, PlantX recently announced a partnership between its wholly owned subsidiary, Bloombox Club Limited (“Bloombox”), a UK-based e-commerce platform that sells and delivers indoor plants, and The Walt Disney Company Limited, a UK-headquartered subsidiary of The Walt Disney Company (The Walt Disney Company (NYSE: DIS). The partnership encompasses a new co-branded campaign to promote Bloombox products and celebrate the release of Disney’s new adventure-filled film, Jungle Cruise (https://ibn.fm/91MgE). As part of the campaign, Bloombox will promote the film’s release by providing exotic plants that go hand in hand with the film, including a new Amazonian plant collection that features Jungle Cruise-inspired terrariums. Bloombox will also give members of its wellness community access to a 10% discount – through the code “JUNGLE10” – on its Amazonian plants, including Jungle Cruise-inspired terrariums, snaky trailing plants, and exotic trees. The campaign will also include a “Hunt for the Healing Tree” treasure hunt on Bloombox’s website, as well as promotion on social media. “Bloombox’s collaboration with Disney is truly a momentous opportunity to celebrate plants and their integral role and impact across the film industry,” commented PlantX Founder Sean Dollinger. “We are beyond thrilled to have Disney’s support in sharing the Bloombox exotic plant collection with our community.” Bloombox CEO Laura Dinnage noted that the company, which believes that connecting with nature is invaluable for all ages, was excited to get involved with Disney’s campaign and introduce a new generation to plants. She further intimated that the new Jungle Cruise-inspired terrarium is the perfect activity for kids this summer and that the company has many more exotic plants that have just launched at Bloombox. “It’s so exciting for us at the company, in the first 18 months of being in operation, to have a company like the largest entertainment company in the world, Disney, to really want to partner with a company like PlantX. It legitimizes our presence in the plant-based space,” Lorne noted in the Proactive interview. Lorne further stated that while PlantX has also partnered with other great vendors and leaders in the e-commerce space, including Walmart (NYSE: WMT) and Hudson’s Bay, this specific partnership with Disney buttresses the fact that the company is indeed a true player in the plant-based space. PlantX, a high-growth technology company, is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, brick-and-mortar stores, and a home delivery system for recipes, meals, products, and more. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research
• The Vancouver-based company was formed in 2019 as the ‎first psychedelic umbrella platform
• The Delic self-sustaining Ecosystem covers three main areas: media, health, and science
• On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company, a legacy counterculture distributor of psychedelic media
• An estimated $238 billion is spent annually in the U.S. on mental health treatments and ancillary services
• University-led and FDA-approved studies are positioning North America as a leading region in the advancement of psychedelics for therapeutic, medical, and recreational use

Delic Holdings (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas. The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more. While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach. The Big Problems Delic Is Addressing

• Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
• Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
• Traditional palliative care methods do not eradicate end-of-life (“EOL”) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
• Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast. The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (“KICs”), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date. The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology. Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market. Latest Acquisition – Homestead Book Company On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits. The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications. The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020. Market Outlook The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

• 32 million people in the U.S. have used psychedelics at least once
• 17% of all American adults between 21 and 64 have used psychedelics at least once
• $500 billion is spent in the U.S. every year on prescription drugs
• $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
• The anxiety disorder and depression treatment market is estimated at $16 billion
• $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014. Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability. Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets. Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue. For more information, visit the company’s website at https://deliccorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• The two crypto space leaders have signed an agreement that will form backbone of ISWH’s phase-one launch of cryptocurrency hosting, mining operation in Georgia
• “Bitmain is probably the most recognizable name in the mining space,” said ISWH CEO
• China’s recent crackdown on cryptomining creates added opportunity, making ISWH-Bitmain partnership even more promising

ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in renewable energy cryptocurrency mining, is teaming up with Bitmain Technologies, the world’s leading producer of cryptocurrency mining hardware and a leading global cryptocurrency mining firm (https://ibn.fm/pjea0). The two crypto space leaders have signed a cryptocurrency mining hosting agreement that will form the backbone of ISWH’s phase-one launch of its cryptocurrency hosting and mining operation in Georgia. “Bitmain is probably the most recognizable name in the mining space, and we are excited that they will be a major piece of our success in Georgia,” said Alonzo Pierce, ISW Holdings president and chair. “Once our 200 MW power tranche is fully utilized, we anticipate annualized revenues of over $200 million, but that will only close the first phase of our vision. We look forward to discussing our next phases in due course. If we are able to execute according to our full vision, we have the potential to drive exponential revenue growth ahead.” Irene Gao, Antminer BD director over the NCSA region, is equally optimistic about the new partnership. “We are excited to have signed this new pioneering project to begin cooperation with ISW Holdings, a new milestone for the industry for creating hosting facilities overseas. The 200 MW facility is the first phase of our long-term partnership, utilizing renewable energy as its source. We expect to further expand this project into the future to support the development of the industry.” The United States is gaining momentum in the cryptocurrency hosting space as the result of China’s recent crackdown on cryptocurrency mining (https://ibn.fm/qC7bg). A “Forbes” article reported that “mining is set to become a whole lot easier (and profitable) for North American crypto miners, thanks to the Chinese government’s aggressive crackdown on the industry. Until recently, China accounted for between 65% and 75% of all Bitcoin mining. Market dominance is expected to shift to North America, though, after an estimated 90% of China’s Bitcoin mining capacity has been ordered to shut down due to concerns over its environmental impact.” This added opportunity makes the ISWH-Bitmain partnership even more promising. “We are grateful for the opportunity to work closely with some of the best in the business,” said Pierce. “Bitmain has solidified itself as a trailblazer in the cryptocurrency mining industry, and we look forward to a bright future together in Georgia.” Bitmain Technologies is a multinational semiconductor company with state-of-the-art IC design capabilities. The company offers products, including chips, servers and cloud solutions for blockchain and artificial intelligence (“AI”) applications. According to Frost & Sullivan, Bitmain is among the world’s top 10 fabless IC designers and China’s second largest. In the blockchain mining area, Bitmain has shipped billions of ASICs, accounting for 75% of the global market. “We are grateful for the opportunity to work closely with some of the best in the business,” said Pierce. “Bitmain has solidified itself as a trailblazer in the cryptocurrency mining industry, and we look forward to a bright future together in Georgia.” ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands and anticipated marketplace needs. The company meets those needs through a variety of strategic innovative processes. ISW Holdings is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• Cybin subsidiary achieved certain milestones as outlined in acquisition agreement
• Adelia brought numerous advantages to company
• Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO

Cybin’s (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting several key advantages gained through the transaction (https://ibn.fm/KZusD). In part, the benefits include novel psychedelic molecules that diversify Cybin’s development portfolio and provide access to multiple future indications; a range of technologies related to novel therapeutics, delivery methods and therapeutic regimens, including six patent applications; an expanding library of psychedelic derivative drug-development candidates, with the first lead compounds slated to enter clinical studies this year; and seasoned leaders who bring extensive clinical and commercialization experience with major drugs, including Allegra (fexofenadine), Sabril (vigabatrin), Anzemet (dolasetron) and Vaniqa (eflornithine). In addition, Cybin strengthened its presence in the United States with ownership of Adelia’s operating development facility in the epicenter of the Boston biotechnology center. “We are thrilled to join forces with Adelia,” said Cybin CEO Doug Drysdale. “We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects. Adelia’s expertise across multiple molecules and multiple indications could potentially give Cybin the ability to address gaps across a larger domain.” At the time of the acquisition, Adelia had built an impressive reputation as an innovative biopharmaceutical company committed to addressing unmet mental health needs through developing proprietary psychedelic therapeutics with improved dosing efficacy and therapeutic indices. Adelia’s leadership team had worked with pharmaceutical companies including Johnson & Johnson, GlaxoSmithKline, Sanofi, Roche, Pfizer and Eli Lilly; they also had impressive academic research affiliations, including with MIT, Harvard, Stanford, Yale and Northeastern University. Since the acquisition, the Cybin and Adelia teams have been focused on a three-pillar development strategy, including a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; efficient drug delivery to enhance dosing control; and a potential novel treatment regimen. Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials
• Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall perform
• TRP-8803 and TRP-8802 are psilocybin-based products being evaluated under Tryp’s PFN program
• Tryp intends to use TRP-8802 in the Phase 2a clinical trials, while TRP-8803 will be used in Phase 2b clinical trials and beyond

The San Diego-based pharmaceutical company, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), has amply prepared for its Phase 2 clinical trials by leveraging high quality collaborations. For the Phase 2a studies, the company will work with the University of Michigan, the University of Florida, and Clinlogix, and to facilitate the advancement of TRP-8803 into Phase 2b clinical trials for chronic pain and eating disorders, respectfully. Tryp announced on July 7, a partnership with the University of Michigan as part of a series of upcoming bridging studies (https://ibn.fm/r71NY). A little over a month later, Tryp announced on August 10 new agreements with Calvert Labs, an Altasciences company and preclinical contact research organization (“CRO”), and Gad Consulting Services (https://ibn.fm/X59p6) that constitute the second batch of the upcoming bridging studies. As part of the agreement with Calvert Labs, the CRO will design and execute exploratory preclinical studies required for Tryp’s proprietary, psilocybin-based compound, TRP-8803, before initiating clinical studies with the novel drug product. The preclinical studies will entail generating toxicology and blood exposure level data for the flagship product. Later, Tryp will work with Altasciences to perform clinical pharmacology studies in healthy, volunteer patients with TRP-8803, thus enabling the use of TRP-8803 in the planned Phase 2b clinical trials for chronic pain and eating disorder indications. On its part, Gad Consulting Services, an internationally acclaimed toxicology consultant serving the pharmaceutical industry in the areas of preclinical and early clinical evaluation, safety assessment, and risk assessment, will advise on certain aspects of the studies Calvert Labs shall perform. “This partnership marks an important milestone for us as we continue to build momentum towards our Phase 2b clinical studies with our proprietary TRP-8803 formulation,” said Tryp Therapeutics President and Chief Science Officer Jim Gilligan, Ph.D. “Calvert Labs and Gad Consulting Services are ideally suited to perform these important studies given their international expertise in toxicology. Our work with these organizations and with Altasciences will accelerate our time into the clinic with TRP-8803.” The TRP-8803, along with TRP-8802, are the flagship psilocybin-based products for Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program, which targets eating disorders such as binge eating disorder, hypothalamic obesity, and others, as well as chronic pain conditions, including fibromyalgia, phantom limb pain, complex regional pain syndrome, and others (https://ibn.fm/ESRgw). Tryp intends to proceed directly into a Phase 2 clinical trial by leveraging preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803. It has divvied up the Phase 2 clinical trials into Phase 2a and Phase 2b. Phase 2a trials will assess the efficacy and safety of TRP-8802, which is an oral form of the psilocybin-based compound, while Phase 2b trials will involve the use of TRP-8803, a formulation with a novel method of administration. Tryp will also use TRP-8803 for Phase 3 trials. The bridging studies are expected to build momentum as the company gears towards these Phase 2b trials, in addition to helping strengthen Tryp’s intellectual property (“IP”) for the TRP-8803 drug product. Based on the July 7 announcement, more bridging studies could still be in the works. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• CDC reports epilepsy is growing problem, 3.4 million people afflicted in the US
• According to report, adult cases rose from 2.3 million to 3 million between 2010 and 2015, pediatric cases increased 450,000 to 470,000 over same period
• Brain Scientific produces patented devices that can be used to provide instant EEG tests to millions of US hospital patients each year

More Americans are suffering from epilepsy than ever before, according to a report by the Center for Disease Control (“CDC”) that states that at least 3.4 million people live with the disorder in the United States (https://ibn.fm/PmF2b). Brain Scientific (OTCQB: BRSF), a New York City based commercial stage healthcare company, aims to address the problem with two FDA-cleared products that can be used to provide instant electroencephalogram (“EEG”) tests to millions of patients subject to seizures in US hospitals each year. According to Brain Scientific’s corporate presentation (https://ibn.fm/IQ6xG), roughly four million emergency department and one million ICU patients are possibly subjected to seizures each year, and that number is expected to rise significantly. The CDC confirms the rising incidence of the disease with statistics from 2015 stating that adult cases rose from 2.3 million to 3 million between 2010 and 2015, and pediatric cases increased 450,000 to 470,000 over the same period. “Millions of Americans are impacted by epilepsy, and unfortunately, this study shows cases are on the rise,” said CDC Director Brenda Fitzgerald, M.D. “Proper diagnosis is key to finding an effective treatment – and at CDC we are committed to researching, testing, and sharing strategies that will improve the lives of people with epilepsy.” With patents already approved in the United States, China and Europe, Brain Scientific’s first commercialized devices – the NeuroCap(TM) and NeuroEEG(TM) – offer low-cost, disposable and portable alternatives to existing time-intensive and costly solutions. The NeuroCap is a disposable pre-gelled EEG headset that features 22 electrodes and 19 active EEG channels that adhere to the international 10-20 system, and the NeuroEEG is a compact, portable, and cost-effective clinical-grade wireless EEG amplifier. Used together both devices can acquire, record, display and transmit electrical brain activity in nearly any setting, including urban emergency departments, intensive care units, community and rural hospitals, neurology practices, primary care/internal medicine clinics, pain management clinics, sleep labs, nursing homes, and mobile diagnostic and treatment clinics. Brain Scientific intends to take its devices beyond on-site brain diagnostic imaging with the use of cloud-powered technology and artificial intelligence (“AI”) and machine learning (“ML”) algorithms that will enable precision diagnosis by neurology specialists. Founded in 2015, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. went public in 2018. The Company is dedicated to developing innovative, cost-effective, and portable medical devices that aim to expand the neurology market and make brain diagnostic imaging increasingly accessible to a large range of diverse, rapidly growing markets. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Entertainment technology innovator Friendable is pioneering a platform that boosts artists’ ability to brand and market themselves as well as fans’ ability to discover, follow and interact with artists
• Friendable’s Fan Pass platform has been approved by both the Apple App and Google Play stores, making it available now for download to mobile devices
• Friendable has signed thousands of Fan Pass artists to its platform during the past year, and is open to musicians at all levels of professional development
• As the company moves to shore up its revenue projections, it is also preparing to develop a series of NFTs for their artists, fans and digital collectors

Marketing and mobile entertainment technology innovator Friendable (OTC: FDBL) is honing its music for the masses platform, following up on an Aug. 5 announcement that its Fan Pass livestream app was approved by both Apple and Google stores with the Aug. 11 rollout of video trailers that show the company’s focus on serving music artists and their fans, existing and new. Friendable’s company mission to put its Fan Pass platform on a path to becoming “the world’s #1 fan experience app” means introducing a platform that helps musicians brand themselves creatively and get their content in front of fans, thanks in part to a dedicated team of social broadcasters deployed to supplement livestream concerts with exclusive interviews and behind-the-scenes content as well as VIP experiences for fans. The Fan Pass app is now available for download on mobile devices worldwide, as well as accessible via the desktop web application, according to the company. The platform includes opportunities to have instant access to favorite artists, prompts for new artist offerings and event scheduling, merch shopping, video delivery on demand, and upgraded artist dashboard featuring tools to organize performances, ticketing and fan-to-artist tipping, among other features. “Today, we achieve a tremendous milestone as we welcome our existing artists and fans to an entirely new platform and experience and prepare to push the Fan Pass brand to the masses with our next set of marketing and awareness initiatives,” Friendable CEO Robert A. Rositano Jr. stated (https://ibn.fm/IRHrF). “Collectively, our team, artists, fans, partners and shareholders have delivered valuable insights, which have produced what we believe is a superior platform for artists at every level of their careers and for the fans who love them or are waiting to discover them.” The new trailers showcase the Fan Pass platform both from an artist standpoint as well as a fan standpoint. “Now that we have successfully released version 2.0 of our Fan Pass platform, along with updating all brand messaging and websites, our focus has turned toward our digital media assets and delivering a campaign that converts to downloads, artist registrations, merchandise sales and fan subscriptions,” Rositano added (https://ibn.fm/ZiChP). The upgraded 2.0 version of the platform’s release coincides with the anniversary of its introduction a year ago. Having met a number of milestones over the past few months, Friendable is now moving into its next phase of growth, which includes converting artists and fans into fee-based service offerings, merchandise sales and generally metrics that show how the company’s revenues are growing and what the Company believes its projections will be over the next few years. Among the company’s planned innovations are non-fungible token (“NFT”) offerings and contests geared toward the fans. NFTs are becoming a particularly popular avenue for monetizing fan interactions with artists — music artists beginning to take on a significant share of the trending enterprise. NFTs involve creating and selling digital rights as collectibles that can be traded in a potentially appreciating market. In April, Friendable announced a letter of intent with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) to develop the musical artist-driven NFTs (https://ibn.fm/pD7uY). For more information about Friendable or the Fan Pass platform, services and offering, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Microdose Psychedelic Insights will host the upcoming Psychedelic Capital: August 2021 conference on August 31, 2021
• Part of a dedicated investor conference series, the conference will host presentations from companies within the functional mushrooms, and psychedelic-based medical therapies sectors

Microdose Psychedelic Insights (“Microdose”) will host their virtual Psychedelic Capital: August 2021 conference on August 31, 2021. The event will play host to a number of companies from across the psychedelics industry, including, but not limited to, the functional mushrooms and phytopharmaceutical sectors. Microdose Psychedelic Insights, a cutting-edge media company focused on creating content, financial analysis, and engaging events in the psychedelics industry, is quickly establishing itself as the industry-leader by using its unique vision and innovative events to help shift the global perception of psychedelic medicine. Part of an investor conference series diving deep into psychedelic medicine investment, Microdose’s Psychedelic Capital conference seeks to introduce investors and attendees to a curated group of CEOs, capital advisors and investment luminaries from around the world. This year’s August conference will be inaugurated by an introductory talk, delivered by Patrick Moher, CEO of Microdose Psychedelic Insights; and Richard Skaife, founding partner at The Conscious Fund, an early-stage venture capital investor within the plant powered medicine sector. The conference will also showcase a number of corporate presentations from companies focused on medicinal mushroom products, the cultivation and processing of pharmaceutical and medicinal cannabis, psychedelic-based In addition, the event will also feature an exciting roundtable symposium centred around the latest ongoing developments and breakthroughs in the global psychedelics industry. Other panel topics being discussed in this edition of Psychedelic Capital are Big Boards and Diversity & Inclusion. An example of one of this month’s panels is Two Eyed Seeing: Bridging Western Science and Indigenous Wisdom. From Steven Huang (he/him), Founder of Millennial HR Design: “Two-eyed seeing is a Mi’kmaw principle for mindfully bringing together Western science and Indigenous wisdom, using all our understandings so we can leave the world a better place. We’ll discuss how cross-cultural collaboration – across the diverse array of psychedelic stakeholders – could be the key to unlocking tremendous value and growth in an ethical, responsible way.” “Microdose is proud to host this important discussion regarding Indigenous wisdom and cross-cultural collaboration in the psychedelic medicine space. We strive to create safe, accessible and inclusive events for all—and partner with organizations who are advancing diversity and equity in psychedelics.”- Cristina Cassen, Chief of Staff, Microdose Psychedelic Insights For more information regarding the details of the event, please visit https://ibn.fm/5t3Dt

• American Cannabis Partners provides organic medical-grade and recreational cannabis through sustainable and environmentally friendly growing practices
• 80% of production output supplies manufacturing, distribution, and retail licenses, 20% is distributed to select California distributors or will be sold under ZÜK brand at company retail location in Michigan
• Company leverages Link4 Corporation’s cloud-powered software and environmental control technology to develop specialized strains, maximize yields, reduce operating costs

American Cannabis Partners (“ACP”), a privately-owned large-scale organic cannabis cultivation company, is committed to business operations that provide top-quality medical-grade and recreational cannabis while positively impacting the environment with sustainable growing practices. American Cannabis Partners supplies multiple forms of raw cannabis product at consistent wholesale prices, produced across its 560,000 square feet of licensed canopy space. Eighty percent of the company’s cultivation operations supply its manufacturing, distribution, and retail licenses, while the remaining twenty percent, consisting of specialized proprietary strains, is either distributed to select California distributors or under ZÜK – its exclusive in-house brand that will be sold at its Michigan retail location. American Cannabis Partners’ organic operating model reduces the company’s environmental footprint and increases its social responsibility using locally purchased production inputs, environment-friendly products, energy and water conservation efforts, and a comprehensive waste management program.  Through this multi-pronged approach, the company endeavors to positively impact its “triple bottom line” that, according to American Cannabis Partners COO Gary Coltek, includes “the planet, people, and profits.” Not all cannabis is alike in terms of quality, effectiveness, and purity. American Cannabis Partners strives to separate itself from its competitors using production methods that emphasize soil health and sustainable farming practices while leveraging innovative technology to monitor the production process and enforce strict environmental controls. The company’s partnership with Link4 Corporation, a market-leading provider of cloud-powered software and environmental management technology, enables American Cannabis Partners to optimize greenhouse production and optimize inputs between harvests. Along with maximizing yields, the use of Link4’s technology allows the company to develop specialized strains while maximizing yields and reducing operating costs. “It is always important for growers to not only monitor their grow environments closely, but also have the ability to compare, track, and graph the data and relationships between different harvests,” said Stephen Scherer, CEO of Link4 Corporation (https://ibn.fm/gRDQn). “This is especially true when an MSO like American Cannabis Partners is working on strain development.  We are pleased to hear that through ACP’s utilization of the Link4 Cloud, they feel they have everything they need to ensure their environment is operating within ideal parameters.” Based in Trinity County of the Emerald Triangle of Northern California, American Cannabis Partners focuses on real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with over 30 years of cannabis industry experience, American Cannabis Partners aims to capture emerging opportunities in real estate and licensing in states that have recently passed cannabis legalization. The company’s expansion plans include additional cultivation licenses at its Trinity County location, along with land acquisition and project development strategies to expand to a third U.S. state in Q2-2022 and a fourth in 2024. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• Company’s patented DehydraTECH(TM) technology is showing the potential of reducing healthcare costs by improving oral medication administration – using capsule and pill form over injection administration
• Lexaria’s offering could potentially offer accelerated regulatory filing with the FDA and other regulators around the world
• The company sub-licenses its DehydraTECH technology for the delivery of fat-soluble active molecules and drugs while also operating four subsidiary companies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, recently announced results from an anti-viral drug molecular characterization study performed by the National Research Council (“NRC”). Results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with Lexaria’s patented DehydraTECH(TM) technology. The use of DehydraTECH could preserve the ability of this form of drug delivery to qualify for an accelerated regulatory filing with the United States Food and Drug Administration (“FDA”), plus other regulators around the world. DehydraTECH provides a potential for cost savings to the health care system by delivering anti-viral drugs more effectively through oral administration. Medication delivery through pill form instead of a shot could potentially help governments or health insurance companies save billions of dollars in administration costs. Chris Bunka, CEO of DehydraTECH, says that DehydraTECH’s speed and efficacy in delivering a bigger fraction of the drug into the patient’s bloodstream are a result of the technology allowing the drug to bypass the liver and instead enter blood circulation via the lymphatic system. “One of the reasons people hate taking any drugs is side effects. It might cause diarrhea, headaches, sleepiness, but because (with DehydraTECH) we can use a smaller quantity of drug to achieve the same result, side effects go down,” Bunka further explained (https://ibn.fm/VX4Wr). Lexaria is currently focused on the applications of DehydraTECH for the administration of hypertension medication but the technology has multiple applications to improve absorption rates for substances ranging from nicotine and cannabinoids to anti-viral medication, including COVID-19 applications. After finalizing current clinical studies on hypertension, the company plans to work with antivirals to help people who need them, especially where vaccination availability is low. The company also sub-licenses the DehydraTECH technology for the delivery of fat-soluble active molecules and drugs. There are currently four subsidiary companies that Lexaria is focusing on, which include different commercial opportunities in their respective industries. These subsidiaries include Lexaria Pharma Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp., and Lexaria Canpharm Corp.

• Lexaria Pharma Corp. – investigates new products for hypertension, antivirals, and other drug classes
• Lexaria Nicotine Corp. – 16.67% owned by Altria Ventures Inc. and investigates the oral, non-combusted tobacco-derived nicotine product format opportunities
• Lexaria Hemp Corp. – pursuing business-to-business opportunities with cannabinoids, including cannabidiol (“CBD”) from hemp
• Lexaria Canpharm Corp. – state-of-the-art Health Canada-licensed lab capable of developing novel psychotropic cannabinoid formulations for potential commercialization in federally legal sectors

Hill Street Beverage Company Inc. (TSX.V: BEER) is one of the companies that sub-licenses the DehydraTECH technology from Lexaria. With the company’s alcohol-free wine popularity, Hill Street Beverage is fueling other strategic priorities, including Hill Avenue Cannabis, using Lexaria’s DehydraTECH technology (https://ibn.fm/1ky4P). Craig Brinkley, Co-CEO of Hill Street, stated that “The acquisition of the global usage rights for patented DehydraTECH from the Lexaria group of companies, aimed at growing our cannabis business worldwide, has also mobilized the company to expand our geographic footprint across all of our business lines including the new global export strategy for alcohol-free beverages.” For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX